UK markets open in 2 hours 19 minutes

Addex Therapeutics Ltd (ADXN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
9.65-0.04 (-0.46%)
At close: 3:33PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 555.8M
Enterprise value 335.44M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)13.99
Price/book (mrq)3.34
Enterprise value/revenue 38.89
Enterprise value/EBITDA 7-2.77

Trading information

Stock price history

Beta (5Y monthly) 1.46
52-week change 3-19.05%
S&P500 52-week change 334.63%
52-week high 335.00
52-week low 38.88
50-day moving average 39.75
200-day moving average 310.02

Share statistics

Avg vol (3-month) 34.04k
Avg vol (10-day) 31.42k
Shares outstanding 55.69M
Implied shares outstanding 6N/A
Float 2.34M
% held by insiders 10.00%
% held by institutions 18.94%
Shares short (30 Aug 2021) 43.76k
Short ratio (30 Aug 2021) 41.16
Short % of float (30 Aug 2021) 4N/A
Short % of shares outstanding (30 Aug 2021) 40.07%
Shares short (prior month 29 Jul 2021) 4699

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CHF.

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-317.18%

Management effectiveness

Return on assets (ttm)-35.39%
Return on equity (ttm)-72.50%

Income statement

Revenue (ttm)3.99M
Revenue per share (ttm)0.79
Quarterly revenue growth (yoy)15.00%
Gross profit (ttm)-6.47M
EBITDA -12.81M
Net income avi to common (ttm)-12.77M
Diluted EPS (ttm)-2.72
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)18.15M
Total cash per share (mrq)3.19
Total debt (mrq)420.16k
Total debt/equity (mrq)2.56
Current ratio (mrq)5.70
Book value per share (mrq)2.89

Cash flow statement

Operating cash flow (ttm)-11.07M
Levered free cash flow (ttm)-6.3M